Figure 6. Effect of mucin-type glycosylation of α2M on migration and invasion in breast cancer cells. (A) The secretory level of α2M in MDA-MB-231 and MDA-MB-468 cells. (B) The mRNA level of α2M in MDA-MB-231 and MDA-MB-468 cells. (C) The mRNA level of α2M in MDA-MB-468/NC, MDA-MB-468/OE-GALNT6, MDA-MB-468/OE-α2M, MDA-MB-468/OE-GALNT6/α2M. (D) The secretory level of α2M in α2M and GALNT6 OE MDA-MB-468 cells. (E) The levels of O-GalNAcylation in α2M OE and α2M/GALNT6 OE MDA-MB-468 cells were verified by Western blotting using anti-O-GalNAc antibody. The arrow indicates GalNAc-conjugated α2M. β-actin was used as internal control. (F) Mucin-type O-glycosylation of α2M was detected by VVA lectin pull-down assay in MDA-MB-468/OE-α2M and MDA-MB-468/OE-GALNT6/α2M cells. (G–J) Migratory and invasive abilities of MDA-MB-468 cells were compared between knockdown or overexpression of GALNT6 and α2M and corresponding negative control. T6, GALNT6.